hemeonclinx Medical News

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Oncology

For Practicing
Oncologists

Conferences

Jobs

Newsletters

My Library

Topics in
Oncology

Alternative Therapies

Anemia/Polycythemia

BMT/SCT

Basic Science/Genetics

Bone/Cartilage

Breast

Carcinogenesis

Coagulation/Bleeding Dz

Colorectal Cancer/Polyps

Dermatologic Oncology

Diagnostics/Radiology

Economics of Medicine

Endocrine Oncology

GI Oncology

Gynecologic Oncology

Head and Neck

Hepatobiliary/Pancreas

Leukemia/Lymphoma

Lung/Thoracic Oncology

Myeloproliferative Dz

Neurologic Oncology

Pain/Palliative Care

Pediatric Heme/Oncology

Pharmacology/Therapy

Popular Press

Renal/Urologic

Side Effects

Soft Tissue/Sarcoma

Transfusion Medicine

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

For Practicing Oncologists

Technology Advances: CISH technology Facilitates Assay of HER2 Expression
Dorothy J. Schirf, MD, MDLinx Oncology

Today's Oncology News: VEGFb Designated Orphan Drug Status By FDA
D Scott Cunningham MD, PhD, MDLinx Oncology

See all

Oncology, Hematology, cancer journals, cancer articles, oncology conference, cancer medical journals, medical news, cancer, breast cancer, cancer articles, drugs,leukemia, lymphoma, blood, articles, medical diagnosis, chemotherapy, multiple myeloma,interferon, bone marrow, hodgkin's disease, bone marrow transplant, cancer treatment, aml, cml, chronic lymphocytic leukemia, acute lymphocytic leukemia, squamous cell cancer, american society of hematology, radiation oncology, pediatric oncology, american society of clinical oncology, cancer news, prostate cancer, colon cancer, ovarian cancer, cervical cancer, neoplasm, immunosuppression, kaposi's sarcoma, malignancy, mammography, bone marrow transplantation, tamoxifen, leucovorin, 5-FU, carboplatin, stem cell, mutation, genetic, oncogenic, carcinogenic, 5 year survival, stage, progression, metastatic, radical, prostatectomy, end of life, pain control

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry
Haematologica, 05/12/08

Email This Article

Save in My Library

Free Abstract

Rubia JDL et al. - The clinical side effects of granulocyte colony-stimulating factor administration in healthy donors are generally mild. Changes in blood counts were minimal and mainly affected white blood cell counts, which returned to normal values within 2 years after granulocyte-colony stimulating factor administration. No patient developed a hematologic malignancy.

Sponsor

--- TRANSFUSION MEDICINE TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email

Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review
Transfusion, 06/30/08

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
International Journal of Hematology, 07/03/08

Platelet transfusion refractoriness
British Journal of Haematology, 07/21/08

...All of Transfusion Medicine